DNA topoisomerase II (topo II) is an essential nuclear enzyme and is the target for etoposide, which is used in the therapy of childhood acute lymphoblastic leukaemia (ALL). Topo II exists as two isoforms referred to as topo II␣ and topo II␤. To determine whether cellular levels of topo II␣ and ␤ are an important factor in determining drug sensitivity/resistance requires accurate, precise measurements of the two isoforms. We have developed a quantitative Western blotting method to accurately measure the absolute amounts of human topo II␣ and ␤, using recombinant human topo II␣ and ␤ as standards. This quantitative method has been used to assess the efficiency of several commonly used topo II extraction protocols. The extractable amount of topo II␣ and ␤ was found to be salt-dependent. However extraction using the optimal salt concentration was found to be as efficient as extraction with DNase I/Rnase A digestion and SDS solubilisation. Using the optimum extraction procedure and the quantitative immunoblotting method, topo II␣ and ␤ was quantified in cell lines, peripheral blood lymphocytes and in lymphoblasts from children with newly diagnosed ALL.
Introduction
DNA topoisomerase II (topo II) is an essential nuclear enzyme responsible for regulating the topological status of DNA. The enzyme achieves this by transiently breaking one DNA duplex and passing a second DNA duplex through the break, the break is then resealed. 1 Topo II is involved in a number of cellular processes including replication, transcription and the segregation of daughter chromosomes at mitosis and meiosis. [2] [3] [4] In eukaryotic cells topo II activity is derived from two genetically distinct isoforms, termed topo II␣ and topo II␤. The respective roles that these two isoforms play in cellular functions are still under investigation.
Type II topoisomerases are a major target for a variety of antineoplastic agents including the epipodophyllotoxins etoposide and teniposide. 5, 6 These drugs allow topo II to cleave DNA but prevent the religation steps catalysed by the enzyme. As a consequence, covalent topo II-DNA adducts ('cleavable complexes') accumulate and interact with other cellular pro- cesses, which can lead to cell death by necrosis or apoptosis. 7, 8 Acquired drug resistance by tumours is a major problem in cancer chemotherapy, however at present the relative contributions of topo II␣ and ␤ to drug resistance is not known. One key mechanism of resistance to anti-topo II drugs is decreased formation of covalent topo II-DNA adducts. This can be due to qualitative changes in the enzyme such as altered catalytic activity and/or DNA cleavage, or altered enzyme levels. Downregulation of the expression of topo II renders the cells less sensitive to drugs which stabilise the topo II cleavable complexes. In some cell lines selected for resistance to antitopo II drugs, the levels of topo II␣ have been shown to be reduced. 9, 10 In addition, levels of topo II␤ rather than topo II␣ have been found to serve as a marker for drug resistance in some cell lines. 11, 12 Consequently, alterations in the relative amounts of the two isoforms could result in or contribute to resistance.
To determine whether acquired resistance has resulted from decreases in the levels of topo II␣ and/or ␤ requires accurate, precise measurements of the protein levels of both isoforms.
Here we present a quantitative immunoblotting protocol to accurately quantify the absolute amount of topo II␣ and ␤ in cell extracts by comparison to a protein standard curve, utilising recombinant human DNA topo II␣ and ␤. 13, 14 This system has been used to determine the relative extraction efficiencies of previously published methods for analysing topo II protein levels. Using the optimum extraction procedure, the amount of topo II␣ and ␤ in proliferating and plateau phase human leukaemia cell lines and resting human peripheral blood lymphocytes (PBL) has been analysed. In addition, to test the potential clinical use of this methodology, topo II levels were quantified in lymphoblasts from children with ALL.
Materials and methods

Cell culture
CCRF-CEM, Molt 4 and Jurkat cells were derived from the peripheral blood of a 4-year-old Caucasian female, a 19-yearold male and a 14-year-old male, respectively. Each of these individuals was diagnosed with ALL and each of these cell lines has been described as a T cell leukaemia line. K562 cells were established from a pleural effusion of a 53-year-old Cau-Leukemia casian female with chronic myelogenous leukaemia (CML) in terminal blast crisis. Raji cells were derived from a Burkitt's lymphoma of the left maxilla of an 11-year-old Negro male and are lymphoblast like. These cell lines were grown in RPMI 1640 supplemented with 3 mM L-glutamine, 10% foetal bovine serum, 25 U/ml penicillin and 25 g/ml streptomycin at 37°C in a humidified atmosphere containing 5% CO 2 . Cell lines were tested for contamination with mycoplasma and found to be negative.
Preparation of whole cell and nuclear extracts
Whole cell extracts were prepared as previously described by either NaCl extraction, 15 digestion with DNase I/RNase A 16 or SDS solubilisation. 5 Preparation of nuclear extracts in which topo II␣ and ␤ were extracted using 1 M NaCl were carried out as described previously. 17 Protein concentrations of extracts were determined with the Bradford protein assay using bovine serum albumin (BSA) as a standard.
Immunoblot analysis and quantitation of topo II␣ and ␤
Whole cell extracts were mixed 1:1 with 2 × SDS-PAGE loading buffer (10% glycerol, 2% SDS, 1% bromophenol blue, 12.5% stacking buffer (3% Tris, pH 6.8), 0.5% ␤-mercaptoethanol) and heated to 68°C for 3 min prior to loading. SDS-polyacrylamide gels (1.5 mm thick; 7% stacking gel and 5% resolving gel) were run using a Consort Bioblock E455 apparatus at 8 V/cm for 5 h. The proteins were transferred from the gel on to Protran nitrocellulose membrane (Schleicher and Schuell, Dassel, Germany) in 25 mM Tris-HCl pH 8.3, 192 mM glycine and 20% methanol at 100 mA overnight using a Trans-blot electrophoretic transfer cell (BioRad, Hercules, CA, USA). Nitrocellulose blots were blocked with 3% BSA in Tris buffered saline (TBS) for 1 h and probed with a rabbit anti-topo II␣ polyclonal raised to full length recombinant human topo II␣ or a rabbit anti-topo II␤ polyclonal raised to a recombinant human topo II␤ C-terminal fragment 18 appropriately diluted into 3% BSA/TBS. Blots were incubated with antibody for 2 h at room temperature. Following 2 × 5 min washes in TBS containing 0.5% Tween-20 (TTBS) and 1 × 5 min wash in TBS, the blots were then incubated with 125 I-labelled second anti-rabbit IgG antibody (ICN Biochemicals, Basingstoke, UK; 0.263 Ci/ml in 3% BSA/TBS) for 2 h at room temperature. The blots were then washed twice in TTBS, then once in TBS (each wash was 5 min) and then air dried. The blots were then exposed to a Phosphor screen over night (Molecular Dynamics, Amersham, UK). The screen was scanned using a phosphorimager (Molecular Dynamics) and the band intensities quantified using an Imagequant computer program.
Mononuclear cell separation
Human lymphocytes or lymphoblasts were separated from peripheral blood or bone marrow aspirates, respectively, by first diluting the sample 1:1 in sterile phosphate buffered saline. The sample was then layered on to sterile 'Lymphoprep' solution (Nycomed, Oslo, Norway) (8 ml of Lymphoprep to 2 ml of sample) and centrifuged at 1100 g for 15 min without the use of a brake. The monolayer containing the lymphocytes or lymphoblasts was then aspirated off using a sterile glass Pasteur pipette.
Topoisomerase II assay
Topo II activity was assessed by decatenation of kinetoplast DNA (kDNA) as described previously.
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Results
Quantitation of topo II␣ and ␤
Western blots were prepared by a standard method, each immunoblot carried three tracks of purified recombinant topo II␣ or ␤ alongside the samples to be analysed to enable the construction of a standard curve. This allowed quantitation under identical transfer and probing conditions. An example of which is shown in Figure 1 , whole cell extracts of CCRF-CEM and PBL were run alongside increasing protein loads of purified recombinant topo II␣ and ␤. Following transfer to nitrocellulose and probing with isoform specific primary and iodinated secondary antibodies, the quantity of 125 I was determined using a phosphorimager and counts were obtained for each band (Figure 1a 
Analysis of topo II␣ and ␤ yield as a function of NaCl concentration
Topo II␣ and ␤ yield was analysed as a function of NaCl concentration in two exponentially growing human leukaemia cell lines from both freshly harvested and frozen cells. Results from freshly harvested cells will be presented first. Topo II␣ and ␤ were quantified in 0.35, 1, 1.4, 1.9 and 2.5 M NaCl whole cell extracts from CCRF-CEM and Jurkat cell lines, the results of three independent experiments are shown in Figure 2a and c. Whole cell extracts were utilised as they were shown to reproducibly yield a greater amount of extractable topo II␣ and ␤ than nuclear extracts (data not shown). Extracts of CCRF-CEM cells ( Figure 2a ) using 1 M NaCl yielded significantly more topo II␣ and ␤ than did 0.35 M NaCl extracts (P = 0.0328 and P = 0.0499, respectively, Student's t-test). The optimal salt concentration for extraction of both ␣ and ␤ from CCRF-CEM cells was 1 M NaCl, yielding equivalent amounts of each isoform (7 × 10 5 monomers per cell). As the NaCl concentration was increased above 1 M, there was a gradual decrease in the amount of topo II␣ and ␤ extracted from CCRF-CEM cells, indeed at 2.5 M NaCl no topo II␣ was detected. Optimal extraction of topo II␣ from Jurkat cells ( Figure 2c ) was seen with 1, 1.4, 1.9 and 2.5 M NaCl, yielding 5 × 10 5 monomers per cell and all five NaCl concentrations yielded similar levels of topo II␤, 2 × 10 5 monomers per cell. The affect of freezing on salt extractability was investigated using cells that had been stored frozen at −80°C. Topo II␣ and ␤ were quantified in 0.35, 1, 1.4, 1.9 and 2.5 M NaCl whole cell extracts from CCRF-CEM and Jurkat cell lines, the results of which are shown in Figure 2b and d. The optimal extraction of topo II from CCRF-CEM frozen cells (Figure 2b ) was seen with 1 M NaCl, the same salt optima observed with fresh cells. However on average more topo II␣ and ␤ was extracted,
Figure 1
Immunoblot analysis of topo II␣ (a) and topo II␤ (b) in CCRF-CEM and PBL whole cell extracts. Lane 1 in each blot contains high molecular weight pre-stained markers. Lane 2 in blot (a) contains 0.8 g of pure topo II␤. Lanes 3 to 6 in blot (a) represent increasing protein loads of pure recombinant topo II␣, 0, 0.6, 1.2 and 1.6 g, respectively. Lane 2 in blot (b) contains 0.6 g of pure topo II␣. Lanes 3 to 6 in blot (b) also represent increasing protein loads of pure recombinant topo II␤, 0, 0.8, 1.6 and 2.4 g, respectively. Lanes 7 and 8 in both blots contain a 149 g protein load of a CCRF-CEM whole cell extract. Lanes 9 and 10 in both blots contain 122 g protein load of a HL-60 whole cell extract. Lane 11 and 12 in both blots contain a 116 g protein load of a whole cell extract of PBL (1.4 × 10 6 cells). All whole cell extracts were prepared using DNase I/RNase A digestion. Calibration curves of purified recombinant topo II␣ and topo II␤ against counts of lanes 3-6 in blots are shown in Figure 1c and d, respectively, enabling quantitation of topo II␣ and ␤ in whole cell and nuclear extracts from their phosphorimage counts. (Figure 2d ) yielded most ␣ and ␤ when extracted with 1 M NaCl, the amount of ␣ was comparable between fresh and frozen cells, whilst ␤ was increased in the extracts from frozen cells.
The levels of topo II␣ and ␤ were also quantified in another three exponentially growing human leukaemia cell lines K562, Raji and Molt 4. This was done using the optimum NaCl concentration from both fresh and frozen cells determined previously. Levels of topo II␣ and ␤ quantified in these cell lines and in CCRF-CEM and Jurkat cells are summarized in Table 1 , along with the optimum NaCl concentration for Leukemia extraction of the two isoforms. In addition, the doubling times of the different cell lines is shown in Table 1 .
Comparison of topo II␣ and ␤ yield using three methods of extraction
Having observed a salt dependence in topo II␣ and ␤ yields in exponentially growing CCRF-CEM and Jurkat cells, salt extraction was compared with two other routinely used methods of extraction, SDS solubilisation and DNase I/RNase A. Topo II␣ and ␤ levels were quantified in both fresh and frozen CCRF-CEM and Jurkat cells using these extraction procedures and the results of three independent experiments are shown in Figure 3 . In the cell line CCRF-CEM, extraction of frozen cells with the optimum NaCl concentration yielded more topo II␤ than when DNase I/RNase A or SDS solubilisation was used. SDS solubilisation yielded the most ␤ from fresh CCRF-CEM cells, whilst DNase I/RNase A extraction produced most ␣ in both fresh and frozen CCRF-CEM cells (Figure 3a) . In the Jurkat cell line, extraction with DNase I/RNase A yielded the greatest levels of the two isoforms from both fresh and frozen cells (Figure 3b) . In summary, quantitation of the two isoforms from these human cell lines was possible with all three methods, although the absolute amounts of topo II␣ and ␤ extracted did vary between the methods, the differences were not significant when using SDS solubilisation or DNase I/RNase A when compared to 1 M NaCl extraction.
Levels of topo II␣ and ␤ in plateau phase cells and resting PBL
Topo II␣ and ␤ levels in the leukaemia cell line Raji during plateau phase were determined using quantitative immunoblot analysis. Extracts using the optimum NaCl concentration (data not shown) were prepared from cells following 168 h continuous culture. (Figure 1 ). No topo II␣ was detected in the PBL using this assay system, however 2.9 × 10 5 monomers per cell of topo II␤ were detected.
Topo II activity in exponentially growing and plateau phase Raji cells and resting PBL
Due to post-translational changes such as phosphorylation and poly ADP ribosylation, 19, 20 the level of topo II protein may not accurately reflect the amount of active enzyme. Hence topo II decatenation activity in exponentially growing Raji and plateau phase Raji nuclear extracts and PBL nuclear extracts were examined to assess this (Figure 4a ). The percentage decatenation activity was plotted against protein level and the amount of protein corresponding to 10% decatenation was calculated by interpolation (data not shown). The percentage of protein from each of the nuclear extracts required to decatenate 10% kinetoplast DNA was then calculated. Activity was then calculated as a percentage of the activity measured in exponentially growing Raji nuclear extracts and the results are shown in Figure 4b . Topo II activity in exponentially growing Raji cells was found to be approximately 70% greater than that of the plateau phase Raji cells and approximately 78% greater than in PBL.
Levels of topo II␣ and ␤ in ALL lymphoblasts
Topo II␣ and ␤ levels in samples of lymphoblasts from 14 cases of newly diagnosed childhood ALL were determined using the quantitative immunoblotting analysis. All 14 individuals were treated with the UKALL XI (92) protocol. 21 (Drugs used in this treatment protocol include allopurinol, prednisolone, vincristine, l-asparaginase, methotrexate, cotrimox-
Leukemia
Figure 3
Topo II␣ and ␤ levels in fresh and frozen CCRF-CEM and Jurkat cells extracted utilising three different methods. Levels of topo II␣ and ␤ expressed as monomers per cell were quantified by immunoblotting analysis in CCRF-CEM (a) and Jurkat extracts (b) made with SDS solubilisation (SDS), DNase I/RNase A digestion (DNase) or 1 M NaCl (1 M). The data represent the mean of at least three independent experiments ± standard error bars. Topo II␣ and ␤ are represented by grey bars and black bars, respectively. azole, daunorubicin, etoposide, cytarabine, thioguanine, mercaptopurine, dexamethasone, cyclophosphamide.) Extraction was carried out using DNase I/RNase A on frozen cells. Extracts were prepared from 1 × 10 7 lymphoblasts and the results are shown in Table 2 . Topo II␣ was not detected in any of the 14 samples, whilst topo II␤ was detected in six of the 14 samples, with a range of between 1.3 × 10 5 and 2.7 × 10 6 monomers per cell.
Discussion
Pure recombinant topo II␣ and ␤ 13,14 have been utilised to enable us to determine the absolute amount of topo II␣ and
Figure 4
Topo II decatenation activity quantified in nuclear extracts of exponentially growing and plateau phase Raji cells and resting PBL. (a) Topo II activity detected in 1 M NaCl nuclear extracts from exponentially growing and plateau phase Raji cells and resting PBL. Activity was measured by the decatenation assay of kDNA as described in the Materials and methods. Reaction mixtures were incubated in the presence of various concentrations of human recombinant topo II␣ (lanes 2-4) and nuclear extracts of exponentially growing Raji cells (lanes 5-8), plateau phase Raji cells (lanes 9-10) and PBL (lanes [11] [12] [13] [14] . Lane 1 contains catenated DNA only. Topo II decatenation activity was then quantified in each of the nuclear extracts as shown in panel b. The percentage of protein from each nuclear extract required to decatenate 10% kDNA was quantified and the data normalised to a value of 100% for the topo II activity in exponentially growing Raji cells. In addition to the total topo II content, the topo II␣ and ␤ content for each cell type is shown.
␤ in human leukaemia cells. Many previous studies have not quantified absolute levels of the two isoforms but instead compared relative levels of the two isoforms. In these studies, topo II␣ and ␤ isoform specific antibodies have been directly compared, ie it has been assumed that both antibodies bind exactly the same number of epitopes on the topo II␣ and ␤ molecules, respectively. However, this may not be the case and therefore the levels of one of the isoforms may have been underestimated. Even when specific monoclonals are used, the epitope recognised may be affected by post-translational modification such as phosphorylation and hence the antibody may only be detecting a fraction of the protein. However the quantitative method described in this paper has a distinct advantage as absolute rather than relative levels of the isoform are detected, thereby enabling more accurate comparisons of the two isoforms.
The results from the salt extractions show that the absolute amount of topo II␣ and ␤ is dependent upon the NaCl concentration used. This is particularly important since some earlier work has predominately used 0.35 M NaCl extracts. For example, Brown et al 11 extracted DNA topo II␣ and ␤ from six established childhood ALL cell lines utilising 0.35 M salt. In our studies a significantly reduced amount of topo II␣ and ␤ was extracted from CCRF-CEM cells when 0.35 M salt was used. In addition, a reduced amount of topo II␣ was extracted in Jurkat cells with 0.35 M NaCl. Therefore, a decreased amount of topo II␣ and/or ␤ may be extracted, thus providing a misleading ratio of the two isoforms. Thus direct comparisons between cell lines and between isoforms within a cell line may not be valid. This has important ramifications for studies of topo II␣ and ␤ levels in cell lines and patient samples, especially when correlating levels of topo II␣ and ␤ to the cytotoxicity generated by topo II poisons or response to chemotherapy.
Increasing the salt concentration above the optima for extraction resulted in a drop in the yield of both enzymes. This may have been due to the formation of high molecular weight aggregates of topo II with other cellular components, The amount of topo II␣ and ␤ in 14 samples of lymphoblasts from children with newly diagnosed ALL was quantified using immunoblot analysis and expressed as the number of monomers per cell. The age, sex, type of ALL, DNA index and the short-term clinical outcome for each patient is shown. DNA index is a measure of ploidy and was reproduced with the permission of Prof ADJ Pearson (Child Health, Royal Victoria Infirmary, Newcastle upon Tyne). ×, these data were not available; −, no detectable topo II.
which were then removed by centrifugation during the extraction procedure. Freezing of whole cells prior to extraction of topo II with NaCl resulted in an increased yield of topo II␣ and ␤ in most cell lines. This may have been due to the disruption of nuclear structures during the freeze thaw process thereby facilitating easier access of the NaCl to the two isoforms and increasing their extraction. The relationship between the doubling times of the different cell lines (Table 1) and topo II␣ and/or ␤ levels was examined. No significant correlation was seen between levels of topo II␣ and/or ␤ quantified and doubling time (data not shown). As these cells were not synchronised, this lack of correlation may have been due to cell to cell heterogeneity of topo II␣ and ␤ content reflecting cell cycle variations in their cellular content. This heterogeneity may have obscured any expected relationship between levels of the two isoforms and doubling time.
In addition to salt extractions, two other methods have been used to prepare whole cell extracts from two cell lines for quantification of topo II␣ and ␤ by immunoblotting, SDS solubilisation and treatment with DNase I/RNase A. When these two methods were compared to extraction at the optimum salt concentration no significant differences were observed. SDS solubilisation and DNase I/RNase A have an advantage in that they are quick, minimising degradation of the topoisomerase, they also work equally well on fresh and frozen cells allowing samples to be frozen prior to analysis which is particularly useful for analysis of patient samples. Samples could be stored for up to 4 weeks either at −80°C or in liquid nitrogen without protein degradation (data not shown). Salt extraction suffers from the disadvantage that the optimal NaCl concentration for extraction needs to be determined. As the DNase/RNase method is technically the least difficult of the three extraction procedures, we recommend that this method be used with a variety of cell types to quantify topo II␣ and ␤ levels. However, it is important to note that this method and SDS solubilisation inactivate protein, so activity assays cannot be performed.
Using our quantitative immunoblotting protocol we have shown that topo II␤ levels were at least comparable to those of topo II␣ in the exponentially growing leukaemia cell lines Leukemia CCRF-CEM, Raji, Molt-4 and K562, when optimal extraction conditions are utilised. This contrasts with previous studies where the levels of topo II␣ exceeded those of topo II␤ in proliferating cells. [22] [23] [24] For example, in a proliferating fibroblast NIH-3T3 cell line extracted with 425 mM NaCl, topo II␣ was found to represent 77% of the total topo II, whereas ␤ represented only 23%. 25 Whilst these discrepancies may reflect the different cell types used it is possible that these previous studies have underestimated the levels of topo II␤. However it is difficult to directly compare measurements between laboratories since they have generally been qualitative comparisons of the two isoforms. These results obtained using this quantitative assay indicate that topo II␤ is not a minor isoform. This is extremely important as the ␤ isoform has also been shown to be an in vivo target for topo II poisons. 6, [26] [27] [28] It is important to note therefore that when examining the relation between topo II levels and cytotoxicity, both isoforms are examined.
The results show that topo II␤ levels exceeded those of topo II␣ in plateau phase Raji cells, as shown previously. 24, 29, 30 Levels of the two isoforms in these plateau phase cells were also lower than in exponentially growing Raji cells, again in agreement with previous studies. 29, 31 No topo II␣ was detected in the PBL, however 2.9 × 10 5 topo II␤ monomers per cell were detected. Previously, resting PBL were shown to contain no detectable levels of topo II␣. These data suggest 31 that both topo II␣ and ␤ are expressed to higher levels in exponentially growing cells than in plateau phase and G 0 (PBL) cells. In plateau phase and G 0 cells, topo II␤ is expressed to a higher level than topo II␣. The activity data from the exponentially growing and plateau phase Raji cells and PBL (Figure 4b) suggests that there is a positive correlation between topo II protein content and topo II activity, ie as topo II protein content increases the amount of topo II activity also increases. This indicates that the measurement of topo II protein levels is predictive of biological activity. In addition it suggests that topo II␤ contributes to topo II activity in these nuclear extracts although to what extent is not clear as the activity of the two isoforms cannot be distinguished. However, it is important to note that although no topo II␣ was detected in PBL this does not suggest that resting PBL do not contain any topo II␣ but rather that topo II␣ levels in these cells are below the detection limit of this assay.
Topo II␣ could not be detected in any of the samples of lymphoblasts from 14 children with newly diagnosed ALL, however topo II␤ was detected in six samples. This lack of detectable topo II␣ in patient samples could be due to the proliferative status of the cells. A study by Hirt et al, 33 showed that the proportion of ALL blasts in S phase was low and that 70-80% of the blasts were in G 1 . As topo II␣ has been shown to be required at lower levels than topo II␤ in G 0 and G 1 cells, 22, 24, 29, 30 this could account for the lack of detectable topo II␣ in the samples. Therefore topo II␤ was the predominant isoform in six of the patient samples. The absolute amount of topo II␤ varied greatly between patients, in some cases up to a 20-fold difference was seen. Previous papers have also found that topo II content varied widely in adult acute myeloid leukaemia (AML) and adult ALL. 34, 35 However, unlike our results, topo II␣ and ␤ protein levels were found to be expressed at similar levels in most patient samples, with only a few samples containing a predominance of either isoform. Yet in a recent study by Zhou et al 36 in agreement with our data, a pronounced variation in topo II␤ levels was found and no topo II␣ could be detected in any of 24 adult AML patients examined.
The lack of detectable topo II␣ in all of the patient samples and the predominance of the topo II␤ isoform in the six of the 14 patient samples examined in this study has important ramifications for the treatment of childhood ALL. Particularly since certain anti-topo II drugs have been shown to differentially target the two isoforms in vitro and in vivo. Cytotoxicity data in murine embryonic fibroblasts derived from topo II␤ knockout mice suggest that this isoform is an important target for the cytotoxic effects of mitoxantrone and amsacrine. 27 However, it is important to note that only 14 samples have been analysed in the present study. Therefore quantitation of topo II␣ and II␤ levels in a much larger sample size is required in order to investigate whether other samples of lymphoblasts from children with ALL will display similar levels of the two isoforms as those already examined. In addition, the quantitative topo II immunoblotting assay could be used to investigate whether levels of topo II␣ and ␤ in lymphoblasts from children with ALL determine response to topo II-targeting agents, both at the time of diagnosis and at relapse. If this hypothesis is proven, precise measurements of topo II␣ and ␤ in childhood ALL lymphoblasts and a detailed knowledge of drug action may in the future lead to the tailoring of topo II-targeted chemotherapy in individuals. This could be achieved for example by decreasing treatment intensity in children with good prognostic factors and increasing treatment intensity, or substituting alternative therapy for children with poor prognostic factors. It is hoped that this will maximise the probability of cure and in addition minimise the risk of severe side-effects generated by the chemotherapy.
